Form 8-K - Current report:
SEC Accession No. 0001140361-22-019249
Filing Date
2022-05-16
Accepted
2022-05-16 07:55:16
Documents
14
Period of Report
2022-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10037527_8k.htm   iXBRL 8-K 29509
2 EXHIBIT 99.1 brhc10037527_ex99-1.htm EX-99.1 67765
6 image00001.jpg GRAPHIC 4874
  Complete submission text file 0001140361-22-019249.txt   253229

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20220516.xsd EX-101.SCH 3959
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20220516_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20220516_pre.xml EX-101.PRE 16066
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10037527_8k_htm.xml XML 4243
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 22925565
SIC: 2834 Pharmaceutical Preparations